CRBN and plasma cell myeloma: In addition, CRBN expression was reported to not affect response to other anti-myeloma agents, which may explain why we found no association between the two CRBN polymorphisms and response to CTD therapy (including thalidomide and two other agents) (Schuster et al. 2014).